- WKN: A0LD6E
- ISIN: DE000A0LD6E6
- Land: Deutschland
Nachricht vom 23.11.2021 | 15:01
Gerresheimer AG: Gerresheimer successfully issues promissory loan - transaction again significantly oversubscribed
Gerresheimer successfully issues promissory loan - transaction again significantly oversubscribed
Duesseldorf, November 23, 2021 - Gerresheimer AG has reached another milestone in the realization of its financing strategy by successfully issuing a new promissory loan. The total volume amounts to EUR 150 m, with the funds helping the company to further improve its financing costs. The transaction was once again significantly oversubscribed due to favorable conditions.
On November 23, 2021, Gerresheimer AG concluded the placement of a new promissory loan to refinance several tranches from previous transactions. Once again, the company managed to improve the already favorable financing conditions. "Gerresheimer remains firmly on a course of profitable, sustainable growth," said Gerresheimer AG Chief Financial Officer, Dr. Bernd Metzner. "Many investors are convinced by our robust business model and want to participate in our long-term success. The new, significantly oversubscribed promissory loan replaces previous obligations while achieving a further improvement in the terms and conditions."
The promissory loan tranches have terms of three and five years and feature fixed and variable rates of interest. The funds from the promissory loans will be used to settle the repayments due in 2022 of certain tranches from previous promissory loan transactions. Repayments for the refinanced promissory loans will be disbursed in September 2022 and November 2022. Up until this point, proceeds from the current promissory loan issue will be utilized to reduce the drawdown on the Gerresheimer AG revolving credit facility. The transaction was supervised by Commerzbank, Landesbank Baden-Württemberg, and UniCredit.
Investor Relations contact
End of Media Release
Issuer: Gerresheimer AG
Key word(s): Finance
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1251389|
|End of News||DGAP Media|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 18:19 Musterdepot-Titel BHP: Es geht voran
03. Dezember 19:02 Dow Jones: Es hört nicht auf...
03. Dezember 19:50 Commerzbank und Deutsche Bank: "Bitte keine großzügige ...
03. Dezember 20:20 Apple unter Druck – aber die Lage hellt sich langsam auf
03. Dezember 21:33 Schlussglocke: Dow Jones schließt schwache Woche mit weiterem Minus ab
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021